



SEQUENCE LISTING

RECEIVED
AUG 08 2002
TECH CENTER 1600/2900

<110> MAZARS, ANDREW P.
JONES, Terence R.

<120> DIAGNOSTIC PROBES AND THERAPEUTICS TARGETING uPA AND uPAR

<130> 38369-169219

<140> US 09/670,537

<141> 2000-09-27

<150> US 60/157,012

<151> 1999-10-01

<160> 2

<170> PatentIn version 3.0

<210> 1

<211> 44

<212> PRT

<213> Homo sapiens

<400> 1

Ser Asn Glu Leu His Gln Val Pro Ser Asn Cys Asp Cys Leu Asn Gly
1 5 10 15

Gly Thr Cys Val Ser Asn Lys Tyr Phe Ser Asn Ile His Trp Cys Asn
20 25 30

Cys Pro Lys Lys Phe Gly Gly Gln His Cys Glu Ile
35 40

<210> 2

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<221> misc_feature

<222> ()..()

<223> uPA active site-targeting compound

B1

<220>

<221> misc_feature

<222> (1)..(1)

<223> Xaa can be any amino acid

<220>

<221> misc_feature

<222> (2)..(2)

<223> Xaa can be any amino acid

<220>

<221> misc_feature

<222> (3)..(3)

<223> Xaa can be any amino acid

<220>

<221> misc_feature

<222> (4)..(4)

<223> Xaa can be any amino acid

<220>

<221> misc_feature

<222> (5)..(5)

<223> Xaa can be any amino acid

<220>

<221> misc_feature

<222> (6)..(6)

<223> Xaa can be any amino acid

<220>

<221> misc_feature

<222> (1)..(2)

<223> Xaa at positions 1 and 2 must be present

<220>

<221> misc_feature

<222> (3)..(6)

<223> Xaa at positions 3 to 6 may be present

<220>

<221> misc_feature

<222> (7)..(7)

<223> Xaa can be Lys or Arg

<400> 2

Xaa Xaa Xaa Xaa Xaa Xaa Xaa

1

5

Blind

